That is the question seemingly unaddressed in the announcement. Reading between the lines 7 completed more than six months treatment and 2 more than 10 months. Assuming that the 2 patients are not a subset on the 7, that means it appears 5 of 14 didn’t survive 6 months. If median survival is 5.5 months this suggests the median survival isn’t much longer with use of Amplia’s agent. Cue the outrage from the true believers.
ATX Price at posting:
8.0¢ Sentiment: None Disclosure: Held
